Continues Execution of Strategic Transformation and Advancement of Biologics Pipeline FREMONT, CA / ACCESS Newswire / November 14, 2025 / Tivic Health® Systems, Inc. (Nasdaq:TIVC), a diversified immunotherapeutics company, today announced financial results for the third quarter and nine months ended September 30, 2025 and provided a business update. "Following our discussions at the Military Health System Research Symposium and continued engagement with key government agencies, we are encouraged by the inte ...

Core Insights - Tivic Health Systems, Inc. has optimized key device and treatment parameters for ncVNS, enhancing its effectiveness through personalization [1] Company Developments - The company collaborated with The Feinstein Institutes for Medical Research at Northwell Health to conduct a study on ncVNS treatment [1] - Key parameters optimized include frequency, amplitude, electrode positioning, and duration of stimulation [1] Study Findings - Personalizing the frequency of ncVNS stimulation led to a 46% increase in heart rate variability, which was 8.9 times more effective than using a uniform frequency across all subjects [1] - The optimal ncVNS frequency varied between subjects and visits, highlighting the need for personalized stimulation parameters before each treatment [1] - Certain electrode placements and configurations were found to significantly impact heart rate variability, with some placements increasing it while others decreased it [1] - A duration of four minutes of ncVNS stimulation was sufficient to achieve a substantial increase in heart rate variability, proving more effective than twenty minutes of stimulation [1]